Treatment Companion App: a record of published content

Public information from Ibogaine.org.nz describes the Treatment Companion App as a clinical record containing clinician-entered screening information, physiological values measured with separate equipment, clinician-configured prompts, assessment records and dated follow-up entries.

The published record fields include risk status, record stage, the latest clinician-entered QTc value and prompts awaiting clinician review. The published limitations state that physiological data are not sensed, observed or acquired directly from a patient; clinicians independently take measurements with separate equipment and enter the values. This app does not replace clinical care. Ibogaine is available in New Zealand by prescription only.

Published screening and intake content

The published screening fields cover cardiac history, QT-prolonging medicines, liver function and substance history, together with clinician-entered cleared, caution or contraindicated decisions.

The medication and psychedelic-readiness content includes clinician-entered prescription, over-the-counter, supplement, herbal and recreational-use details, including amount, frequency and last-taken date. Interaction-reference records include an evidence source, evidence level, named reviewer and review date. Additional fields cover antidepressant history, prior withdrawal experience and prescriber contact details; no content advises stopping or tapering a medicine.

The published record is arranged across 11 stages from registration to post-treatment follow-up. Clinician decision fields include reviewed, more information required, specialist referral required and not currently ready, alongside a readiness report for the prescriber.

Published physiological-value and prompt fields

The published fields contain physiological values and QTc measurements taken independently by clinicians with separate equipment. Clinician-configured and clinician-reviewed prompt parameters include QTc values at 460 ms and 500 ms, bradycardia below 50 bpm, desaturation and hypotension. These decision-support fields do not represent autonomous sensing, detection or diagnosis.

The public information lists eight clinical record templates containing distinct checklists, suggested recording intervals and observation-window fields. These descriptions identify record content only and are not instructions about administration or effects.

Published assessment and follow-up content

The published assessment content includes calculated scores and charts based on clinician-entered PHQ-9, GAD-7, craving, sleep and mood responses, together with clinician-review fields. These scores do not diagnose a condition. The record also contains a clinician-maintained adverse-event register and actions-taken fields.

The published follow-up content includes dated entries at 1 week, 1 month, 3 months and 6 months, with attached assessment forms.

Scope of this public-health summary

This article summarizes third-party public information published by Ibogaine.org.nz. It does not provide instructions about ibogaine administration, effects or clinical decision-making.

The described content comprises documentation, screening and clinical record-support fields. Screening decisions, threshold prompts and calculated scores are clinician-configured and clinician-reviewed decision-support information. The published limitations exclude direct patient observation, diagnosis, prescribing and changes to medicine use. This app does not replace clinical care. Ibogaine is available in New Zealand by prescription only. Source: Ibogaine.org.nz.